Eubel Brady & Suttman Asset Management Inc. Takes $17.32 Million Position in Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Eubel Brady & Suttman Asset Management Inc. bought a new stake in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBTGet Rating) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 17,321,627 shares of the company’s stock, valued at approximately $17,322,000. Global Blood Therapeutics comprises approximately 2.8% of Eubel Brady & Suttman Asset Management Inc.’s investment portfolio, making the stock its 16th biggest holding. Eubel Brady & Suttman Asset Management Inc. owned approximately 26.61% of Global Blood Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Nisa Investment Advisors LLC grew its holdings in Global Blood Therapeutics by 75.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company’s stock worth $52,000 after buying an additional 650 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Global Blood Therapeutics in the 1st quarter worth approximately $448,000. Candriam Luxembourg S.C.A. grew its holdings in Global Blood Therapeutics by 16.7% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 756,708 shares of the company’s stock worth $26,211,000 after buying an additional 108,369 shares in the last quarter. Fairmount Funds Management LLC grew its holdings in Global Blood Therapeutics by 59.1% in the 1st quarter. Fairmount Funds Management LLC now owns 1,182,307 shares of the company’s stock worth $40,955,000 after buying an additional 439,307 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. grew its holdings in Global Blood Therapeutics by 44.3% in the 1st quarter. Vestmark Advisory Solutions Inc. now owns 12,669 shares of the company’s stock worth $439,000 after buying an additional 3,892 shares in the last quarter.

Global Blood Therapeutics Price Performance

GBT opened at $67.75 on Wednesday. The stock has a fifty day moving average of $52.96 and a 200-day moving average of $37.97. The firm has a market capitalization of $4.57 billion, a P/E ratio of -13.52 and a beta of 0.46. Global Blood Therapeutics, Inc. has a 12-month low of $21.65 and a 12-month high of $73.02. The company has a quick ratio of 6.17, a current ratio of 6.88 and a debt-to-equity ratio of 4.92.

Global Blood Therapeutics (NASDAQ:GBTGet Rating) last released its earnings results on Monday, August 8th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.07). The business had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $64.39 million. Global Blood Therapeutics had a negative net margin of 137.30% and a negative return on equity of 170.37%. During the same quarter in the previous year, the company earned ($1.12) EPS. Equities analysts forecast that Global Blood Therapeutics, Inc. will post -4.7 EPS for the current fiscal year.

Insider Transactions at Global Blood Therapeutics

In other news, insider Nazila Habibizad sold 4,678 shares of the company’s stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $67.19, for a total value of $314,314.82. Following the transaction, the insider now directly owns 8,918 shares of the company’s stock, valued at $599,200.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Nazila Habibizad sold 4,678 shares of the company’s stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $67.19, for a total value of $314,314.82. Following the transaction, the insider now directly owns 8,918 shares of the company’s stock, valued at $599,200.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Philip A. Pizzo sold 1,260 shares of the company’s stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $27.25, for a total transaction of $34,335.00. Following the completion of the transaction, the director now directly owns 9,112 shares in the company, valued at $248,302. The disclosure for this sale can be found here. 4.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on GBT. SVB Leerink lowered Global Blood Therapeutics from an “outperform” rating to a “market perform” rating and set a $68.50 price objective for the company. in a report on Tuesday, August 9th. Cowen downgraded Global Blood Therapeutics to a “market perform” rating and upped their target price for the stock from $67.00 to $68.50 in a research report on Tuesday, August 9th. Wedbush downgraded Global Blood Therapeutics to a “neutral” rating in a research report on Monday, August 15th. William Blair downgraded Global Blood Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, August 8th. Finally, Stifel Nicolaus restated a “hold” rating on shares of Global Blood Therapeutics in a research report on Monday, August 8th. Twelve analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Global Blood Therapeutics currently has a consensus rating of “Hold” and an average target price of $65.50.

Global Blood Therapeutics Company Profile

(Get Rating)

Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.

Featured Articles

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.